Ethics statement
scabies
SCABIES
The trial had ethical approval from the Solomon Islands Health Ethics Review Board (HRE005/18) and Royal Children’s Hospital Human Research Ethics Committee, Melbourne, Australia (38099A), and was prospectively registered with Australian New Zealand Clinical Trials Registry ACTRN12618001086257. We obtained written informed consent from all participants aged 18 years and above, and from parents/guardians of those aged less than 18 years.We conducted this study in Western Province in Solomon Islands, a Pacific island country with an estimated population in 2021 of around 700,000 people [The cluster-randomised design has been used for this study as we aim to assess the impact of a public health intervention on a community, rather than individual participants. The cluster-randomised design aims to replicate real-world conditions which can include population movement in and out of villages, coverage gaps and other factors that may influence the outcome. The study will measure the change in scabies prevalence on a village level rather than tracking individuals.Villages were randomly assigned by an independent statistician, in a 1:1 ratio, to MDA with either one dose (Arm 1) or two doses administered 7–14 days apart (Arm 2) of scabies treatment (